Project Grant HT94252510152

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $391,553 to Viewpoint Molecular Targeting, Inc. to develop an image-guided, targeted alpha-particle therapy for the treatment of metastatic high-grade serous ovarian carcinoma (HGSOC). The goal is to commercialize a new alpha-particle radiotherapy approach that combines Viewpoint's proprietary radionuclide chelation and production technologies with an innovative "pretargeting"...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Sloan-Kettering Institute for Cancer Research provides $720,416 over 5 years to develop a novel theranostic (therapeutic-diagnostic) CAR-T cell approach for treating neuroendocrine prostate cancer (NEPC). The key objectives are to: 1) Evaluate the therapeutic efficacy of DLL3-specific CAR-T cells in NEPC models, 2) Develop DLL3/PSMA bi-specific CAR-T cells to target...

The National Cancer Institute (NCI) awarded a 2-year, $1,453,091 Cooperative Agreement to The Trustees of the University of Pennsylvania for the project "Dual-Targeted DOTA CAR T Cells with Image-Guided Monitoring for Solid Tumor Treatment" under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The project aims to develop an image-guided, adaptable chimeric antigen receptor (CAR) T cell therapy platform that can be precisely controlled and tracked in vivo using...

The National Cancer Institute awarded Immunova Therapeutics LLC a $1,001,029 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop a CD4+ T cell receptor (TCR)-engineered immunotherapy for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) generate a GMP-grade Master Cell Bank and viral particles for the IMT-422 (CD4 TCR-STEM T cell) product, and 2) evaluate the pharmacokinetics, biodistribution, and toxicity of the IMT-422...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,408,844.00 to the Sloan-Kettering Institute for Cancer Research to characterize the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate. The key objectives are to utilize a DLL3-targeted radiolabeled monoclonal antibody for non-invasive diagnosis using PET imaging (89Zr-DFO-SC16.56 AB) and as an image-based therapy...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $235,707 to Weill Medical College of Cornell University to characterize somatostatin receptor 2 (SSTR2) expression in pituitary neuroendocrine tumors (PitNETs) using [68Ga]-Dotatate PET/MRI. The goal is to improve diagnostic accuracy, increase understanding of PitNET biology, and enhance stereotactic radiosurgery (SRS) targeting to improve local...

The National Cancer Institute (NCI), through its Cancer Treatment Research program (CFDA 93.395), has awarded a $402,402 R21 project grant to the University of Louisville's Office of Research & Innovation. The goal of this 2-year grant, which began on September 19, 2023, is to develop and evaluate a novel tumor glycobiomarker-targeting agent called AVFC Lectibody as a potential immunotherapeutic and diagnostic agent against non-small cell lung cancer (NSCLC). The research aims to assess...

The National Cancer Institute (NCI) awarded the University of Texas Health Science Center at Houston (UTHealth) a $571,271 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop a targeted drug conjugate for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The key objectives are to: (1) synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate containing the microtubule inhibitor cryptophycin, (2) visualize and quantify...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The Regents of the University of California, San Francisco (UCSF) to complete rigorous preclinical validation of a novel radioimmunotherapy (RIT) for the treatment of acute myeloid leukemia (AML). The key objectives of this $678,101 award, spanning March 2025 to February 2030, are to evaluate the preclinical efficacy, toxicity, and combination efficacy of a 7065-based RIT...

This $692,072 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of novel theranostic agents for managing aggressive subtypes of prostate cancer. The funded research aims to synthesize PSMA-targeted poly(amidoamine) (PAMAM) dendrimer-based theranostic agents capable of: (i) highly specific PSMA targeting; (ii) quantitative PET/CT imaging for patient selection; (iii) incorporation of a...